Clinical Trial On Lectranal Completed

A double-blind placebo controlled clinical trial confirms efficacy and safety of Lectranal® in treating seasonal allergic rhinitis. Over a period of 6 weeks 78.6% of patients in the Lectranal® group had significant or moderate improvement compared to 38.5% in the placebo group. Lectranal® had statistical significantly better results for several outcome measures in comparison to the placebo. Lectranal® had strong positive effect on the reduction of SARS and Mini RQLQ score as well as on the improvement in individual allergy symptoms. more

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.